|Security||LMB / Limbach Holdings, Inc. (53263P105)|
|President and CEO||Bacon Charles A. III|
|Industry||Construction Special Trade Contractors|
|Institutional Shares||2,309,667 - 30.62%|
|Common Stock Shares Outstanding||7,542,249 shares (as of 2018-03-31)|
|Institutional Value||$ 28,265,000 USD|
TFSC / 1347 Capital Corp.|
LMBH / Limbach Holdings, Inc
LMBHW / Limbach Holdings, Inc
Institutional Stock Ownership and Shareholders()
Limbach Holdings, Inc. (NASDAQ:LMB) has 24 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,309,667 shares.
Largest shareholders include
State of New Jersey Common Pension Fund D, Dimensional Fund Advisors Lp, Perritt Capital Management Inc, Arbor Wealth Management, LLC, Legato Capital Management LLC, Argent Capital Management Llc, Vanguard Group Inc, Acuitas Investments, Llc, New Jersey Better Educational Savings Trust, and NJ State Employees Deferred Compensation Plan.
Limbach Holdings, Inc. (NASDAQ:LMB) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/lmb"><img src="https://images.fintel.io/us-lmb-so.png" alt="LMB / Limbach Holdings, Inc. Institutional Ownership"><a>
|VANGUARD GROUP INC||19,831||108,444||446.84||275||1,342||388.00|
|Mesirow Financial Investment Management, Inc.||37,093||21,199||-42.85||453||251||-44.59|
|State of New Jersey Common Pension Fund D||644,000||644,000||0.00||8,907||7,973||-10.49|
|ACK Asset Management LLC||200,000||0||-100.00||2,766||0||-100.00|
|UBS Group AG||0||4,763||0||58|
|NEXT CENTURY GROWTH INVESTORS LLC||143,614||0||-100.00||1,986||0||-100.00|
|Renaissance Technologies LLC||0||13,500||0||165|
|ARGENT CAPITAL MANAGEMENT LLC||111,180||1,359|
|PERRITT CAPITAL MANAGEMENT INC||288,050||285,050||-1.04||3,984||3,572||-10.34|
|DIMENSIONAL FUND ADVISORS LP||447,839||458,904||2.47||6,194||5,681||-8.28|
|WELLS FARGO & COMPANY/MN||2,158||0||-100.00||30||0||-100.00|
|CWA Asset Management Group, LLC||12,680||11,380||-10.25||175||139||-20.57|
|Tower Research Capital LLC (TRC)||90||8,061||8,856.67||1||99||9,800.00|
|SILVER CAPITAL MANAGEMENT LLC||14,236||38,686||171.75||197||189||-4.06|
|MANUFACTURERS LIFE INSURANCE COMPANY, THE||4,132||2,716||-34.27||57||33||-42.11|
|Acuitas Investments, Llc||50,060||620|
|LPL Financial LLC||41,240||42,540||3.15||570||520||-8.77|
|ESSEX INVESTMENT MANAGEMENT CO LLC||21,077||18,394||-12.73||291||225||-22.68|
|Steward Partners Investment Advisory, Llc||8,846||9,724||9.93||122||118||-3.28|
|MACQUARIE GROUP LTD||8,100||17,906||121.06||112||219||95.54|
|Arbor Wealth Management, LLC||80,308||213,553||165.92||1,110||2,695||142.79|
|DEUTSCHE BANK AG\||6,800||11,100||63.24||94||135||43.62|
|New Jersey Better Educational Savings Trust||48,000||46,000||-4.17||664||569||-14.31|
|NJ State Employees Deferred Compensation Plan||42,000||43,000||2.38||581||532||-8.43|
|Legato Capital Management LLC||140,005||140,005||0.00||1,711||1,655||-3.27|
|Advisor Group, Inc.||230||3|
9h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
11h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
Limbach Holdings, Inc. (NASDAQ:LMB) Q1 2018 Results Earnings Conference Call May 16, 2018 9:00 AM ET (1-1)
The following slide deck was published by Limbach Holdings, Inc in conjunction with their 2018 Q1 earnings call. (1-0)
Trump’s latest announcement of pulling out United States from the Obama-era Iran deal and reimposing powerful sanctions on the OPEC nation didn’t roil the stock market as expected. Then again, rising yields, a strengthening dollar and geopolitical uncertainty are continuously threatening the nine-year bull run. Amid widespread volatility, it is difficult to make wise investment decisions. As such, honing in on corners of the market that are expected to outperform could serve us better. (9-0)
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 24th: (5-0)
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 20th: (3-0)
as of ET